Ryan J R
Am Heart J. 1985 May;109(5 Pt 2):1131-6. doi: 10.1016/0002-8703(85)90697-0.
The clinical pharmacology and pharmacokinetics of acebutolol are summarized. Acebutolol and its longer-acting metabolite, diacetolol, are rapidly absorbed into the circulation from the gastrointestinal tract, and their bioavailability, unlike that of propranolol and metoprolol, is not significantly altered by whether the patient has recently eaten. Acebutolol is extensively metabolized by the liver, and elimination pathways involve approximately 30% to 40% through renal excretion and 50% to 60% by nonrenal mechanisms, including the bile and direct passage through the intestinal wall. The decreased hepatic metabolism and renal clearance rates seen in elderly patients may lead to the accumulation of both acebutolol and its metabolite, as has been reported with propranolol. In studies conducted to ascertain acebutolol's possible effect on common concurrently administered medications, the drug did not significantly alter either serum digoxin levels or serum insulin levels in diabetic patients treated with tolbutamide, nor did it change prothrombin time in patients treated with sodium warfarin.
醋丁洛尔的临床药理学和药代动力学总结如下。醋丁洛尔及其长效代谢物双醋洛尔从胃肠道迅速吸收进入循环，与普萘洛尔和美托洛尔不同，患者近期是否进食对其生物利用度无显著影响。醋丁洛尔在肝脏中广泛代谢，消除途径约30%至40%通过肾脏排泄，50%至60%通过非肾脏机制，包括胆汁和直接通过肠壁。老年患者肝脏代谢和肾脏清除率降低，可能导致醋丁洛尔及其代谢物蓄积，普萘洛尔也有类似报道。在确定醋丁洛尔对常用同时服用药物可能影响的研究中，该药物对用甲苯磺丁脲治疗的糖尿病患者的血清地高辛水平或血清胰岛素水平均无显著影响，对用华法林钠治疗的患者的凝血酶原时间也无改变。
